Extracellular matrix glycosaminoglycans (ECM GAGs)

Extracellular matrix glycosaminoglycans (GAGs) are highly negatively charged, unbranched polysaccharides that serve as critical scaffolds within the extracellular environment (StatPearls, 2023). They are categorized into four main groups: heparin/heparan sulfate, chondroitin/dermatan sulfate, keratan sulfate, and hyaluronic acid, each distinguished by their sugar composition and sulfation patterns (NCBI, 2022). GAGs are essential for tissue hydration, structural integrity, and the regulation of cell signaling by acting as co-receptors for various growth factors and cytokines (PubMed, 2021). In clinical practice, GAGs are significant therapeutic targets and agents; for instance, heparin is a cornerstone anticoagulant that accelerates antithrombin III activity, while hyaluronic acid is utilized for viscosupplementation in osteoarthritis (DrugBank, 2024). Dysregulation of GAG metabolism or structure is linked to numerous pathologies, including mucopolysaccharidoses, atherosclerosis, and cancer metastasis, where they modulate the tumor microenvironment (PubMed, 2021). Current drug development efforts focus on GAG mimetics and inhibitors of GAG-modifying enzymes to treat inflammatory and fibrotic diseases (Nature Reviews, 2020).

Other names

MucopolysaccharidesGlycosaminoglycansAcidic glycosaminoglycansGAGs

Drugs targeting ECM GAGs typically act by mimicking their natural inhibitory functions, such as heparin binding to antithrombin III to inhibit coagulation, or by replacing depleted GAGs to restore tissue lubrication, as seen with hyaluronic acid in joint therapy (DrugBank, 2024; StatPearls, 2023). Additionally, therapeutic strategies may involve the use of enzymes like hyaluronidase to degrade GAGs and enhance drug penetration through the extracellular matrix (PubMed, 2021).